Brachytherapy seeds work on prostate cancer:
This article was originally published in Clinica
Brachytherapy using Theragenics' radioactive seed implants performed as well as or better than traditional treatments for prostate cancer such as radical prostatectomy and external beam radiation, according to a nine-year US study. Some 83.5% of the 230 stage I and II patients treated with the company's TheraSeed - palladium 103 - implants were cancer-free at nine years, researchers from the Seattle Prostate Institute in Washington reported in the March issue of the International Journal of Radiation Oncology, Biology and Physics. Only 3% of patients experienced prostate cancer recurrence, said Theragenics of Buford, Georgia.
You may also be interested in...
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
Breakthrough solutions based on new biological entities (ADCs and mAbs) are making hope real for patients with conditions of high unmet medical need. Byondis is developing therapies that target intractable cancers and autoimmune diseases and taking precision medicine to the next level.
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.